743405
Last Update Posted: 2017-07-21
Recruiting has ended
All Genders accepted | 18 Years-55 Years |
30 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects
This is a First Time in Human Study to assess the safety, tolerability and pharmacokinetics of single doses of GSK1034702 in healthy subjects. It will be a single-blind, randomized, placebo-controlled, single oral dose, dose-rising, cross-over study in healthy male and female (of non-child bearing potential) subjects. Subjects will be randomized into cohorts of 10 subjects and cohorts will be recruited until the pre-defined safety or PK stopping limits are reached. Each subject will receive placebo and up to 4 doses of GSK1034702 in a randomized sequence on 5 separate study occasions.
Eligibility
Relevant conditions:
Cognitive Disorders
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
Inclusion criteria
Exclusion criteria
locations
Data sourced from ClinicalTrials.gov